Working… Menu

A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00794703
Recruitment Status : Completed
First Posted : November 20, 2008
Last Update Posted : March 28, 2016
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
The objective of this study is to compare the efficacy and safety between Mycamine and Itraconazole oral solution in preventing invasive fungal infections on autologous(malignant blood diseases) or allogeneic hematopoietic stem cell transplant patients

Condition or disease Intervention/treatment Phase
Fungemia Fungal Infections Drug: micafungin (Mycamine) Drug: itraconazole Phase 3

Detailed Description:
Dosing of Mycamine or Itraconazole will start at the beginning of the transplant conditioning regimen or within 48 hours after the transplant conditioning regimen, and administration time should be no longer than 42 days

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 288 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multi-center, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of Mycamine® vs Itraconazole Oral Solution for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoietic Stem Cell Transplant
Study Start Date : November 2008
Actual Primary Completion Date : November 2009
Actual Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1. Micafungin Drug: micafungin (Mycamine)
Other Names:
  • Mycamine
  • FK463

Active Comparator: 2. Itraconazole Drug: itraconazole
Other Name: Sporanox

Primary Outcome Measures :
  1. Treatment success rate (fungal breakthrough rate) [ Time Frame: At the end of the study ]

Secondary Outcome Measures :
  1. Incidence of proven or probable invasive fungal infection [ Time Frame: Throughout the study period ]
  2. The usage rate of systemic antifungal agents [ Time Frame: During 4 weeks after the administration ]
  3. Time to treatment failure [ Time Frame: During the study period ]
  4. Assessment of Adverse events, Laboratory examinations and vital signs evaluation [ Time Frame: Throughout the study period ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients at risk of systemic fungal infections due to their immunocompromised state due to one of the following:

    • Patient with a hematologic malignancy undergoing an autologous hematopoietic stem cell transplant
    • Any patient undergoing an allogeneic hematopoietic stem cell transplant

Exclusion Criteria:

  • Patients with moderate or severe liver disease, as defined by:

    • AST or ALT greater than 5 times upper limit of normal (ULN), OR;
    • Total bilirubin greater than 2.5 times ULN
  • Patients with evidence of a deeply invasive or disseminated fungal infection at time of enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00794703

Layout table for location information
China, Fujian
Fuzhou, Fujian, China
China, Hubei
Wuhan, Hubei, China
China, Sichuan
Chengdu, Sichuan, China
China, Zhejiang
Hangzhou, Zhejiang, China
Jiangsu, China
Nanning, China
Peking, China
Shanghai, China
Tianjin, China
Xian, China
Sponsors and Collaborators
Astellas Pharma Inc
Layout table for investigator information
Study Chair: Use Central Contact Astellas Pharma Inc

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Astellas Pharma Inc Identifier: NCT00794703     History of Changes
Other Study ID Numbers: MCFGCN02-0
First Posted: November 20, 2008    Key Record Dates
Last Update Posted: March 28, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Astellas Pharma Inc:
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Invasive Fungal Infections
Systemic Inflammatory Response Syndrome
Pathologic Processes
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors